Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

被引:346
作者
Levine-Tiefenbrun, Matan [1 ]
Yelin, Idan [1 ]
Katz, Rachel [2 ]
Herzel, Esma [2 ]
Golan, Ziv [3 ]
Schreiber, Licita [3 ]
Wolf, Tamar [3 ]
Nadler, Varda [3 ]
Ben-Tov, Amir [2 ,4 ]
Kuint, Jacob [2 ,4 ]
Gazit, Sivan [2 ]
Patalon, Tal [2 ]
Chodick, Gabriel [2 ,4 ]
Kishony, Roy [1 ,5 ]
机构
[1] Technion Israel Inst Technol, Fac Biol, Haifa, Israel
[2] Maccabitech, Maccabi Hlth Serv, Tel Aviv, Israel
[3] Maccabi Healthcare Serv, Maccabi Mega Lab, Rehovot, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Technion Israel Inst Technol, Fac Comp Sci, Haifa, Israel
基金
以色列科学基金会;
关键词
D O I
10.1038/s41591-021-01316-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Beyond their substantial protection of individual vaccinees, coronavirus disease 2019 (COVID-19) vaccines might reduce viral load in breakthrough infection and thereby further suppress onward transmission. In this analysis of a real-world dataset of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results after inoculation with the BNT162b2 messenger RNA vaccine, we found that the viral load was substantially reduced for infections occurring 12-37 d after the first dose of vaccine. These reduced viral loads hint at a potentially lower infectiousness, further contributing to vaccine effect on virus spread. Breakthrough infections of SARS-CoV-2 occurring 12 or more days after the first dose of the BNT162b2 mRNA vaccine were associated with lower viral loads than those found in unvaccinated individuals, suggesting that the vaccine might reduce infectiousness.
引用
收藏
页码:790 / +
页数:13
相关论文
共 13 条
[1]   Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Dynamics Should Inform Policy [J].
Cevik, Muge ;
Marcus, Julia L. ;
Buckee, Caroline ;
Smith, Tara C. .
CLINICAL INFECTIOUS DISEASES, 2021, 73 :S170-S176
[2]  
Chodick G., 2021, EFFECTIVENESS 1 DOSE, DOI DOI 10.1101/2021.01.27.21250612
[3]   SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn [J].
Connors, Mark ;
Graham, Barney S. ;
Lane, H. Clifford ;
Fauci, Anthony S. .
ANNALS OF INTERNAL MEDICINE, 2021, 174 (05) :687-+
[4]   Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates [J].
Gallagher, Molly E. ;
Sieben, Andrew J. ;
Nelson, Kristin N. ;
Kraay, Alicia N. M. ;
Orenstein, Walter A. ;
Lopman, Ben ;
Handel, Andreas ;
Koelle, Katia .
NATURE MEDICINE, 2021, 27 (01) :4-5
[5]   Temporal dynamics in viral shedding and transmissibility of COVID-19 [J].
He, Xi ;
Lau, Eric H. Y. ;
Wu, Peng ;
Deng, Xilong ;
Wang, Jian ;
Hao, Xinxin ;
Lau, Yiu Chung ;
Wong, Jessica Y. ;
Guan, Yujuan ;
Tan, Xinghua ;
Mo, Xiaoneng ;
Chen, Yanqing ;
Liao, Baolin ;
Chen, Weilie ;
Hu, Fengyu ;
Zhang, Qing ;
Zhong, Mingqiu ;
Wu, Yanrong ;
Zhao, Lingzhai ;
Zhang, Fuchun ;
Cowling, Benjamin J. ;
Li, Fang ;
Leung, Gabriel M. .
NATURE MEDICINE, 2020, 26 (05) :672-675
[6]  
Levine-Tiefenbrun M, ASS COVID 19 RT QPC, DOI [10.1101/2020.10.30.20222935, DOI 10.1101/2020.10.30.20222935]
[7]   VIEWPOINT: COVID-19 Understanding COVID-19 vaccine efficacy [J].
Lipsitch, Marc ;
Dean, Natalie E. .
SCIENCE, 2020, 370 (6518) :763-765
[8]   Rethinking Covid-19 Test Sensitivity - A Strategy for Containment [J].
Mina, Michael J. ;
Parker, Roy ;
Larremore, Daniel B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (22)
[9]   Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [J].
Polack, Fernando P. ;
Thomas, Stephen J. ;
Kitchin, Nicholas ;
Absalon, Judith ;
Gurtman, Alejandra ;
Lockhart, Stephen ;
Perez, John L. ;
Perez Marc, Gonzalo ;
Moreira, Edson D. ;
Zerbini, Cristiano ;
Bailey, Ruth ;
Swanson, Kena A. ;
Roychoudhury, Satrajit ;
Koury, Kenneth ;
Li, Ping ;
Kalina, Warren V. ;
Cooper, David ;
Frenck, Robert W., Jr. ;
Hammitt, Laura L. ;
Tureci, Ozlem ;
Nell, Haylene ;
Schaefer, Axel ;
Unal, Serhat ;
Tresnan, Dina B. ;
Mather, Susan ;
Dormitzer, Philip R. ;
Sahin, Ugur ;
Jansen, Kathrin U. ;
Gruber, William C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) :2603-2615
[10]  
Pollard AJ, 2021, NAT REV IMMUNOL, V21, P129, DOI 10.1038/s41577-020-00497-5